The Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust, Leicester General Hospital, Leicester, UK
Search for other papers by M A Webb in
Google Scholar
PubMed
Department of Diabetes and Endocrinology, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, UK
Diabetes and Endocrinology Department, Kettering General Hospital NHS Foundation Trust, Kettering, UK
Search for other papers by H Mani in
Google Scholar
PubMed
Search for other papers by S J Robertson in
Google Scholar
PubMed
Search for other papers by H L Waller in
Google Scholar
PubMed
Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK
Search for other papers by D R Webb in
Google Scholar
PubMed
Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK
Search for other papers by C L Edwardson in
Google Scholar
PubMed
Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK
Search for other papers by D H Bodicoat in
Google Scholar
PubMed
Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK
Search for other papers by T Yates in
Google Scholar
PubMed
The Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust, Leicester General Hospital, Leicester, UK
Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK
Search for other papers by K Khunti in
Google Scholar
PubMed
The Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust, Leicester General Hospital, Leicester, UK
Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK
Search for other papers by M J Davies in
Google Scholar
PubMed
study randomisation was not taken into account. The aim of the present study was to assess the impact of changes in daily step count over a 6-month period on markers of: inflammation (IL6 and CRP), T2DM (glucose, HbA1c and insulin) and CVD (blood
Search for other papers by Po-Chung Cheng in
Google Scholar
PubMed
Search for other papers by Chia-Hung Kao in
Google Scholar
PubMed
Introduction Type 2 diabetes mellitus (T2DM) is a metabolic disease that induces substantial morbidity in affected patients ( 1 ). Chronic hyperglycemia predisposes patients to microvascular complications including retinopathy, neuropathy, and
School of Public Health, Ningxia Medical University, Yinchuan, Ningxia, China
Search for other papers by Chan Yang in
Google Scholar
PubMed
Search for other papers by Yadi Zhang in
Google Scholar
PubMed
Search for other papers by Juan Li in
Google Scholar
PubMed
Search for other papers by Xiaowei Liu in
Google Scholar
PubMed
Search for other papers by Jiangwei Qiu in
Google Scholar
PubMed
Search for other papers by Jiaxing Zhang in
Google Scholar
PubMed
Key Laboratory of Environmental Factors and Chronic Disease Control, Ningxia Medical University, Yinchuan, Ningxia, China
Search for other papers by Xiuying Liu in
Google Scholar
PubMed
Key Laboratory of Environmental Factors and Chronic Disease Control, Ningxia Medical University, Yinchuan, Ningxia, China
Search for other papers by Yuhong Zhang in
Google Scholar
PubMed
Key Laboratory of Environmental Factors and Chronic Disease Control, Ningxia Medical University, Yinchuan, Ningxia, China
Search for other papers by Yi Zhao in
Google Scholar
PubMed
weight loss due to unknown causes), or a past medical history of T2DM. Prediabetes was defined as a fasting plasma glucose ≥6.1 mmol/L and <7.0 mmol/L. Normoglycemia was defined as a fasting plasma glucose level <6.1 mmol/L. Body mass index (BMI) was
Search for other papers by P R van Dijk in
Google Scholar
PubMed
Diabetes Centre, Departments of Internal Medicine, General Practice, Langerhans Medical Research Group, Department of Internal Medicine, Division of Cell Biology, Faculty of Health Sciences, Isala Clinics, PO Box 10400, 8000 G.K. Zwolle, The Netherlands
Search for other papers by S J J Logtenberg in
Google Scholar
PubMed
Diabetes Centre, Departments of Internal Medicine, General Practice, Langerhans Medical Research Group, Department of Internal Medicine, Division of Cell Biology, Faculty of Health Sciences, Isala Clinics, PO Box 10400, 8000 G.K. Zwolle, The Netherlands
Search for other papers by K H Groenier in
Google Scholar
PubMed
Diabetes Centre, Departments of Internal Medicine, General Practice, Langerhans Medical Research Group, Department of Internal Medicine, Division of Cell Biology, Faculty of Health Sciences, Isala Clinics, PO Box 10400, 8000 G.K. Zwolle, The Netherlands
Diabetes Centre, Departments of Internal Medicine, General Practice, Langerhans Medical Research Group, Department of Internal Medicine, Division of Cell Biology, Faculty of Health Sciences, Isala Clinics, PO Box 10400, 8000 G.K. Zwolle, The Netherlands
Search for other papers by N Kleefstra in
Google Scholar
PubMed
Diabetes Centre, Departments of Internal Medicine, General Practice, Langerhans Medical Research Group, Department of Internal Medicine, Division of Cell Biology, Faculty of Health Sciences, Isala Clinics, PO Box 10400, 8000 G.K. Zwolle, The Netherlands
Diabetes Centre, Departments of Internal Medicine, General Practice, Langerhans Medical Research Group, Department of Internal Medicine, Division of Cell Biology, Faculty of Health Sciences, Isala Clinics, PO Box 10400, 8000 G.K. Zwolle, The Netherlands
Search for other papers by H J G Bilo in
Google Scholar
PubMed
Diabetes Centre, Departments of Internal Medicine, General Practice, Langerhans Medical Research Group, Department of Internal Medicine, Division of Cell Biology, Faculty of Health Sciences, Isala Clinics, PO Box 10400, 8000 G.K. Zwolle, The Netherlands
Search for other papers by H J Arnqvist in
Google Scholar
PubMed
the hepatic sensitivity of GH stimulation and subsequently increases IGF1 production (8) . Furthermore, insulin increases IGF1 bioactivity by a down-regulation of IGFBP1 expression in the liver (5) . In type 1 diabetes mellitus (T1DM), with
Search for other papers by Agnieszka Adamska in
Google Scholar
PubMed
Search for other papers by Vitalii Ulychnyi in
Google Scholar
PubMed
Search for other papers by Katarzyna Siewko in
Google Scholar
PubMed
Search for other papers by Anna Popławska-Kita in
Google Scholar
PubMed
Search for other papers by Małgorzata Szelachowska in
Google Scholar
PubMed
Search for other papers by Marcin Adamski in
Google Scholar
PubMed
Search for other papers by Angelika Buczyńska in
Google Scholar
PubMed
Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland
Search for other papers by Adam Jacek Krętowski in
Google Scholar
PubMed
.8 0.35 T2DM (%) 23 41 <0.01 Hyperlipidaemia (%) 72.4 53.6 0.01 Obesity (%) 34.7 33.9 0.9 CKD (%) 28.5 32.1 0.7 Stroke (%) 2.9 1.8 0.6 STEMI (%) 5 5.4 0.6 NSTEMI (%) 0
Search for other papers by Aldo Bonaventura in
Google Scholar
PubMed
Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Search for other papers by Fabrizio Montecucco in
Google Scholar
PubMed
Search for other papers by Franco Dallegri in
Google Scholar
PubMed
adults with type 1 DM (T1DM) ranges from 0.2 to 3.2 episodes per patient per year (1, 2) and from 0.1 to 0.7 in insulin-treated T2DM patients (2) . In patients with impaired awareness of hypoglycemia (IAH), it is more difficult to have a precise
Search for other papers by Xi Cao in
Google Scholar
PubMed
Search for other papers by Ming Lu in
Google Scholar
PubMed
Search for other papers by Rong-Rong Xie in
Google Scholar
PubMed
Search for other papers by Li-Ni Song in
Google Scholar
PubMed
Search for other papers by Wei-Li Yang in
Google Scholar
PubMed
Search for other papers by Zhong Xin in
Google Scholar
PubMed
Search for other papers by Guang-Ran Yang in
Google Scholar
PubMed
Search for other papers by Jin-Kui Yang in
Google Scholar
PubMed
Introduction The prevalence of type 2 diabetes mellitus (T2DM) is increasing globally, and diabetic complications affect millions of people worldwide ( 1 , 2 ). Diabetic eye diseases, such as diabetic retinopathy (DR) and diabetic macular
Search for other papers by Yuka Goto in
Google Scholar
PubMed
Search for other papers by Yoshie Otsuka in
Google Scholar
PubMed
Search for other papers by Kenji Ashida in
Google Scholar
PubMed
Search for other papers by Ayako Nagayama in
Google Scholar
PubMed
Search for other papers by Nao Hasuzawa in
Google Scholar
PubMed
Search for other papers by Shimpei Iwata in
Google Scholar
PubMed
Search for other papers by Kento Hara in
Google Scholar
PubMed
Search for other papers by Munehisa Tsuruta in
Google Scholar
PubMed
Search for other papers by Nobuhiko Wada in
Google Scholar
PubMed
Division of Endocrinology and Metabolism, Diabetes Center, Kurume Medical Center, Kokubu-machi, Kurume-city, Fukuoka, Japan
Search for other papers by Seiichi Motomura in
Google Scholar
PubMed
Division of Endocrinology and Metabolism, Diabetes Center, Kurume Medical Center, Kokubu-machi, Kurume-city, Fukuoka, Japan
Search for other papers by Yuji Tajiri in
Google Scholar
PubMed
Search for other papers by Masatoshi Nomura in
Google Scholar
PubMed
inhibitor. Materials and methods Study population This prospective, single-center, and single-arm clinical study evaluated 269 patients with T2DM who were admitted to the Kurume University Hospital between July 1, 2017 and December 31, 2018
Search for other papers by Shaomin Shi in
Google Scholar
PubMed
Search for other papers by Xinghua Chen in
Google Scholar
PubMed
Search for other papers by Wen Yu in
Google Scholar
PubMed
Search for other papers by Xiaolan Ke in
Google Scholar
PubMed
Search for other papers by Tean Ma in
Google Scholar
PubMed
decreasing trend in renal GLP-1R protein expression compared with the NC group, which verified that there was a reduction in renal GLP-1R protein expression in the T2DM mouse model. The hypoglycemic effect of Degu insulin does not reverse this change. In this
Search for other papers by Chaiho Jeong in
Google Scholar
PubMed
Search for other papers by Bongseong Kim in
Google Scholar
PubMed
Search for other papers by Jinyoung Kim in
Google Scholar
PubMed
Search for other papers by Hansang Baek in
Google Scholar
PubMed
Search for other papers by Mee Kyoung Kim in
Google Scholar
PubMed
Search for other papers by Tae-Seo Sohn in
Google Scholar
PubMed
Search for other papers by Ki-Hyun Baek in
Google Scholar
PubMed
Search for other papers by Ki-Ho Song in
Google Scholar
PubMed
Search for other papers by Hyun-Shik Son in
Google Scholar
PubMed
Search for other papers by Kyungdo Han in
Google Scholar
PubMed
Search for other papers by Hyuk-Sang Kwon in
Google Scholar
PubMed
,554,830 people aged ≥ 40 years with T2DM underwent a health examination. Patients who had at least one service claim with a diagnosis of T2DM based on ICD-10 (E11–E14) and patients prescribed at least one antidiabetic drug at any time over 1 year were classified